KALPESH BHAVSAR: Open Payments
NPI 1457546913 · ROSEMEAD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,402 in 54 payments from 10 companies in 2025. Trend: 2023 $1,431 · 2024 $1,412 · 2025 $1,402
Food & beverage: $1,402
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 8 | $268 |
| Otsuka America Pharmaceutical, Inc. | 11 | $262 |
| ABBVIE INC. | 10 | $216 |
| Alkermes, Inc. | 5 | $148 |
| Vanda Pharmaceuticals Inc. | 5 | $146 |
| E.R. Squibb & Sons, L.L.C. | 5 | $128 |
| Almatica Pharma LLC | 5 | $112 |
| Janssen Pharmaceuticals, Inc | 3 | $68 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $26 |
Products named: Auvelity, VRAYLAR, ABILIFY ASIMTUFII, ARISTADA, HETLIOZ, COBENFY, LOREEV XR, REXULTI.
Industry payments across CA — which companies pay providers there.
